Investor82,
So you are finally coming around to manufacturing, manufacturing, manufacturing. Good to see this. You do realize that what Slave1 is pointing to is manufacturing readiness from day 1 after approval right?; ). This isn’t pie in the sky stuff, this is readiness on multiple fronts. As you have seen from Slave1’s links, the amount of CDMO capacity in the U.K. has expanded very rapidly over the last 5 years. Much of it is linked to cell and gene treatment production. When the approval decision is announced I expect the IFR funding pathway to get lambasted as anyone with a solid tumor cancer is likely to be told about murcidencel and that only available pathway for reimbursement for a while. I expect that NICE will be receiving the info needed for a reimbursement decision very soon because NWBO isn’t saying anything about that now and by now, with ten year data basically in hand, and Flaskworks headed towards being in process for full validation, they should be. Remember, I said within one year from approval because having manufacturing in proper position for an approval is the key to success. After that, clinical trials and IFRs can go forward full steam. Then all that needs to be answered is who will be the agreed upon sponsors of those trials and will it be pay to play; ). Best wishes.
Market Data 
Markets 
AI
